Volume : 13, Issue : 03, March – 2026

Title:

RECENT ADVANCES IN PHARMACOLOGICAL APPROACHES FOR THE MANAGEMENT OF DIABETES MELLITUS: MECHANISM, THERAPY AND FUTURE PERSPECTIVE

Authors :

Pranav Rajendra Kadam, Sachin Tukaram Kolekar, Sumit Santosh Koli, Aarti Baliram Bansode, Dr. Rahul Ishwara Jadhav

Abstract :

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. The global prevalence of diabetes has increased dramatically in recent decades, making it one of the most significant public health challenges worldwide. Pharmacological management plays a crucial role in controlling blood glucose levels and preventing complications associated with the disease. Traditional antidiabetic drugs such as insulin, sulfonylureas, and biguanides have been widely used for decades. However, recent advances in pharmacotherapy have introduced several novel classes of drugs including DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists targeting multiple metabolic pathways. These therapies offer improved glycemic control with reduced risk of hypoglycemia and additional cardiovascular benefits. This review highlights the pathophysiology of diabetes mellitus, mechanisms of action of various pharmacological agents, recent advancements in antidiabetic drug therapy, and future perspectives for improved management of the disease.
Keywords: Diabetes mellitus, antidiabetic drugs, insulin resistance, SGLT2 inhibitors, GLP-1 agonists, pharmacotherapy.

Cite This Article:

Please cite this article in press Aarti baliram bansode et al., Recent Advances In Pharmacological Approaches For The Management Of Diabetes Mellitus: Mechanism, Therapy And Future Perspective., Indo Am. J. P. Sci, 2026; 13(03).

REFERENCES:

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2023.
2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004.
3. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993.
4. Riddle MC. Metformin therapy in type 2 diabetes. Diabetes Care. 2012.
5. Drucker DJ. Incretin-based therapies for diabetes. Cell Metab. 2006.
6. Zinman B. Empagliflozin and cardiovascular outcomes. N Engl J Med. 2015.
7. Wild S. Global prevalence of diabetes. Diabetes Care. 2004.
8. Fowler MJ. Microvascular complications of diabetes. Clin Diabetes. 2008.
9. Nauck MA. Incretin hormones and diabetes. Diabetologia. 2011.
10. Holman RR. Long-term follow-up of intensive glucose control. N Engl J Med. 2008.
11. Ferrannini E. SGLT2 inhibitors in diabetes management. Lancet Diabetes Endocrinol. 2017.
12. Buse JB. GLP-1 receptor agonists in diabetes therapy. Lancet. 2016.
13. DeFronzo RA. Combination therapy in diabetes treatment. Diabetes Care. 2010.
14. Garber AJ. Pharmacologic therapy for type 2 diabetes. Endocr Pract. 2020.
15. Bailey CJ. Metformin: mechanisms of action. Diabetologia. 2017.
16. Nauck MA. DPP-4 inhibitors in diabetes. Lancet. 2007.
17. Ceriello A. Diabetes and oxidative stress. Diabetes Care. 2000.
18. Brownlee M. Biochemistry of diabetes complications. Nature. 2001.
19. Shapiro AM. Stem cell therapy in diabetes. Lancet. 2000.
20. Chatterjee S. Global burden of diabetes. Lancet Diabetes Endocrinol. 2017.